Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2020-03-20
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients
NCT04944433
Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients
NCT07348913
Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients
NCT01327391
CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19
NCT04487990
Survival Study in Patients Undergoing On-line Hemodiafiltration
NCT00694031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The impressive figures of transmission in different communities underline the need for reorganization of efforts to limit contagion, particularly in crowded settings. Hemodialysis centres represents a specific setting in which many patients are repeatedly treated in the same area at the same time.
Dialysis patients constitute a susceptible population because of their older age, high comorbidity burden and their less efficient immune system. Therefore, they are more prone to develop severe infectious diseases than the general population.. Moreover, if infected, the requirements of specialized resources and staff is further complicated by requirements for isolation, control and prevention, putting healthcare systems under additional strain. Therefore, all measures to slow and to control unmanageably high incidence rates must be taken very seriously.
The routine treatment usually requires three dialysis sessions per week Further, some patients must travel long distances to the dialysis centre. One option to reduce the higher risk of these patients is to reduce the frequency of dialysis sessions.However, the potential benefits of reduced risk may be associated with higher interdialytic weight gain and inadequate dialysis, Two factors that increase the risk of mortality. Furthermore, the impact of reduced frequency on Anemia and Nutrition have not been extensively studied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Two Times
The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
less-frequency hemodialysis
Patients of treatment group would be evaluated quarterly
Three times
Usual thrice-weekly hemodialysis schedule
less-frequency hemodialysis
Patients of treatment group would be evaluated quarterly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
less-frequency hemodialysis
Patients of treatment group would be evaluated quarterly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* amputated lower limbs
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dialisis Madariaga
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esteban L Siga, MD
Role: PRINCIPAL_INVESTIGATOR
Dialisis Madariaga
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dialisis Madariaga
General Juan Madariaga, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
coronavirus
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.